🚨New #LMHR Editorial in JCL!🚨
🙏Please RT🙏
- Cautious consideration for #LMHRs
- Calls for patient-centered approach
- Calls for more research on #LMHRs(!)
AND we raised money from the LMHR community to make this *open access*.
Let's unpack... /1 authors.elsevier.com/a/1g22A6tb2E2O…
🙏Please RT🙏
- Cautious consideration for #LMHRs
- Calls for patient-centered approach
- Calls for more research on #LMHRs(!)
AND we raised money from the LMHR community to make this *open access*.
Let's unpack... /1 authors.elsevier.com/a/1g22A6tb2E2O…
2/ So why is this a big deal?
Two reasons:
For one, this editorial is the first of its kind to gather MDs and PhDs together to help develop a clinical position on the #LMHR phenotype and importance of expanding research around this phenomenon.
That's hard to understate!
Two reasons:
For one, this editorial is the first of its kind to gather MDs and PhDs together to help develop a clinical position on the #LMHR phenotype and importance of expanding research around this phenomenon.
That's hard to understate!
3/ Typically, there have been just two positions on the topic of high LDL on keto, particularly LMHRs.
- Conventional: LMHR *must* lower LDL/ApoB
- LH skeptic: LMHR can ignore LDL/ApoB
This editorial concludes those with high LDL-c/ApoB from keto "should consider" lowering.
- Conventional: LMHR *must* lower LDL/ApoB
- LH skeptic: LMHR can ignore LDL/ApoB
This editorial concludes those with high LDL-c/ApoB from keto "should consider" lowering.
4/ It further qualifies the importance of looking to "competing medical conditions" on this decision as well.
Thus, this is actually a fairly nuanced and moderate position, all things considered.
Thus, this is actually a fairly nuanced and moderate position, all things considered.
5/ Which is why I was excited for this article.
I've been asked several times at this point if I "endorse" it -- but as many of you already know, I don't endorse any individual course of action on changing lipid levels.
I've been asked several times at this point if I "endorse" it -- but as many of you already know, I don't endorse any individual course of action on changing lipid levels.
6/ But I *do* endorse raising greater awareness of opinions and analyses like these that focus more on the specificity of this phenomenon and hope there's more to come.
7/ Obviously, this group of authors (like all of us) will adjust their positions as more data emerge.
But as is often the case with clinicians, they ask, "Is there any kind of document that focuses on this exact phenomenon from a clinical perspective that is available today?"
But as is often the case with clinicians, they ask, "Is there any kind of document that focuses on this exact phenomenon from a clinical perspective that is available today?"
8/ Which brings me to the second big reason: this document couples its clinical approach with a likewise call to action for its research.
And yes, on a personal level, this is very meaningful to see in the JCL. It's a major milestone for moving this research forward.
And yes, on a personal level, this is very meaningful to see in the JCL. It's a major milestone for moving this research forward.
9/ Big thanks to the several dozen members of the LMHR FB group for joining me in covering the not-so-modest Open Access fee so everyone can read this for free.
10/ And mega props to authors:
@nicknorwitz
@MichaelMindrum
Philippe Giral MD
Anatol Kontush PhD
@AdrianSotoMota
@DrRagnar
@DominicDAgosti2
Venkat S. Manubolu MD
And co-senior authors:
@BudoffMd
& Ron Krauss
@nicknorwitz
@MichaelMindrum
Philippe Giral MD
Anatol Kontush PhD
@AdrianSotoMota
@DrRagnar
@DominicDAgosti2
Venkat S. Manubolu MD
And co-senior authors:
@BudoffMd
& Ron Krauss
• • •
Missing some Tweet in this thread? You can try to
force a refresh
